Spryte Medical announces its neuro Optical Coherence Tomography (nOCT) technology, which has received Breakthrough Device designation from the U.S. Food and Drug Administration (FDA). This emphasizes the transformative potential of nOCT in neurointervention and cerebrovascular treatment.
Neuro Optical Coherence Tomography (nOCT) marks a significant advancement in the field of neurointervention. nOCT is used specifically for identifying cerebrovascular pathways.
This cutting-edge imaging technology enables highly detailed visualization of the brain's vascular structure, approaching histological resolution, which enhances diagnostic capabilities and improves treatment accuracy.
Neurointervention has already made a substantial positive impact on managing cerebrovascular disorders, and the introduction of nOCT will further propel advancements in this area.
OCT information could have an even greater impact in neurointervention outcomes and benefits of this technology into the brain for the first time ever.
With this innovative technology, we can achieve a clearer understanding of disease processes and medical devices, ultimately guiding our clinical decisions and improving patient outcomes.
Source: https://www.businesswire.com/news/home/20240722486759/en
